• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)

    2/14/23 4:00:28 PM ET
    $MTCR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MTCR alert in real time by email
    SC 13G/A 1 mtcr282317sc13ga1.htm AMENDMENT NO. 1

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

    SCHEDULE 13G/A

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Metacrine, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    59101E103

    (CUSIP Number)

     

     

     

    December 31, 2022

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

    Page 1 of 8
     

     

    CUSIP No.  59101E103 13G/A Page 2 of 8 Pages

     

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (b) 
    x
    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    4,250,000

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    4,250,000

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    4,250,000

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.98% 

    12

    type of reporting person

     

    pN 

     

    Page 2 of 8
     

     

    CUSIP No.  59101E103 13G/A Page 3 of 8 Pages

     

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (b) 
    x
    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    4,250,000

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    4,250,000

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    4,250,000

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.98% 

    12

    type of reporting person

     

    oo 

     

    Page 3 of 8
     

     

    CUSIP No.  59101E103 13G/A Page 4 of 8 Pages

     

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang

     

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (b) 
    x
    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    united states

     

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    4,250,000

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    4,250,000

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    4,250,000

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.98% 

    12

    type of reporting person

     

    IN 

     

    Page 4 of 8
     

     

    Item 1(a).Name of Issuer:

     

    Metacrine, Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    4225 Executive Square, Suite 600, San Diego, CA 92037

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number: 59101E103

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 4,250,000 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Management. Tang Capital Management beneficially owns 4,250,000 shares of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 4,250,000 shares of the Issuer’s Common Stock.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

    Page 5 of 8
     

     

    The percentages used herein are based on 42,569,515 shares of Common Stock outstanding as of November 9, 2022, as set forth in the Issuer’s Quarterly Form 10-Q that was filed with the Securities and Exchange Commission on November 14, 2022.

     

    (b)Percent of Class:

     

    Tang Capital Partners 9.98%
    Tang Capital Management 9.98%
    Kevin Tang 9.98%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Partners 4,250,000 shares
    Tang Capital Management 4,250,000 shares
    Kevin Tang 4,250,000 shares

     

    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Partners 4,250,000 shares
    Tang Capital Management 4,250,000 shares
    Kevin Tang 4,250,000 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Page 6 of 8
     

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Page 7 of 8
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: February 14, 2023  

     

     

    TANG CAPITAL PARTNERS, LP

     

    By: Tang Capital Management, LLC, its General Partner

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    TANG CAPITAL MANAGEMENT, LLC

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 8 of 8

     

     

     

    Get the next $MTCR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MTCR

    DatePrice TargetRatingAnalyst
    10/22/2021$2.50Outperform → Sector Perform
    RBC Capital Mkts
    10/22/2021$19.00 → $1.00Buy → Hold
    Canaccord Genuity
    10/22/2021$14.00 → $2.00Buy → Hold
    Jefferies
    10/22/2021Buy → Neutral
    HC Wainwright & Co.
    More analyst ratings

    $MTCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement

      LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information regarding the termination of the definitive merger agreement is provided set forth in a Current Report on Form 8-K filed by Metacrine with the U.S. Securities and Exchange Commission today and is available at www.sec.gov and on Metacrine's website under the heading "Investors." About Metacrine Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies t

      12/23/22 4:01:00 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine Reports Third-Quarter 2022 Results

      SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. "We made great progress during the quarter in advancing our proposed merger with Equillium," said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. "We believe that Equillium has demonstrated compelling clinical data in Lupus Nephritis and has an exciting pipeline of clinical programs with multiple upcoming data catalysts and potential value inflection events. Equillium is led by an accomplished leadership

      11/14/22 4:38:48 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Equillium to Acquire Metacrine in All-Stock Transaction

      Expected to add $33 million in cash at closing to Equillium's balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642, an orally delivered Phase 2 ready FXR agonist for ulcerative colitis Preston Klassen, M.D., MHS, to be appointed to the Board of Directors Equillium, Inc. (NASDAQ:EQ) and Metacrine Inc. (NASDAQ:MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024.

      9/6/22 4:00:00 PM ET
      $EQ
      $MTCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products

    $MTCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Metacrine downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Metacrine from Outperform to Sector Perform and set a new price target of $2.50

      10/22/21 7:43:25 AM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Metacrine from Buy to Hold and set a new price target of $1.00 from $19.00 previously

      10/22/21 7:42:38 AM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine downgraded by Jefferies with a new price target

      Jefferies downgraded Metacrine from Buy to Hold and set a new price target of $2.00 from $14.00 previously

      10/22/21 7:42:07 AM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTCR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Metacrine Inc.

      15-12G - Metacrine, Inc. (0001634379) (Filer)

      3/24/23 5:29:55 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - Metacrine, Inc. (0001634379) (Filer)

      3/24/23 5:28:02 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-8 POS filed by Metacrine Inc.

      S-8 POS - Metacrine, Inc. (0001634379) (Filer)

      3/23/23 4:34:58 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Klassen Preston

      4 - Metacrine, Inc. (0001634379) (Issuer)

      3/24/23 12:35:32 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4: York Michael sold $44,331 worth of shares (107,054 units at $0.41), decreasing direct ownership by 51% to 103,499 units (tax withholding)

      4 - Metacrine, Inc. (0001634379) (Issuer)

      1/27/23 4:44:04 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4: Klassen Preston sold $157,266 worth of shares (380,605 units at $0.41), decreasing direct ownership by 41% to 541,905 units (tax withholding)

      4 - Metacrine, Inc. (0001634379) (Issuer)

      1/27/23 4:42:52 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTCR
    Financials

    Live finance-specific insights

    See more
    • Equillium to Acquire Metacrine in All-Stock Transaction

      Expected to add $33 million in cash at closing to Equillium's balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642, an orally delivered Phase 2 ready FXR agonist for ulcerative colitis Preston Klassen, M.D., MHS, to be appointed to the Board of Directors Equillium, Inc. (NASDAQ:EQ) and Metacrine Inc. (NASDAQ:MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024.

      9/6/22 4:00:00 PM ET
      $EQ
      $MTCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products

    $MTCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)

      SC 13G/A - Metacrine, Inc. (0001634379) (Subject)

      2/14/23 4:00:28 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)

      SC 13G/A - Metacrine, Inc. (0001634379) (Subject)

      2/8/23 3:43:35 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Metacrine Inc.

      SC 13G - Metacrine, Inc. (0001634379) (Subject)

      12/19/22 4:00:11 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Metacrine Announces Resignation of Chief Medical Officer

      SAN DIEGO, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that Hubert C. Chen, M.D., chief medical officer, has resigned to pursue a new opportunity. Dr. Chen's resignation is effective December 31, 2021. Preston Klassen, M.D., MHS, chief executive officer, is expected to assume responsibility for Metacrine's ongoing clinical trials and future clinical operations. "We appreciate Hubert's significant contributions during the last three years as we moved our pipeline through several important milestones," said Preston Klass

      12/27/21 8:00:00 AM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors

      SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced the appointment of Julia C. Owens, Ph.D. to the Company’s board of directors, effective April 1, 2021. Dr. Owens will serve as a member of the Compensation Committee.   “We’re excited to welcome Julia as a new independent director,” commented Richard Heyman, Ph.D., Metacrine’s chairman. “She is an accomplished biopharmaceutical executive, with an established track record in building companies, business development, capital formation and strategic partnerships. Juli

      4/5/21 4:05:00 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care